Sanofi Chief Executive Officer, Olivier Brandicourt, commented:
“We have generated solid sales momentum in the third quarter and seen a strong contribution to our financial performance from savings and efficiencies arising from our more focused organization. As a result, we are able to increase our FY 2016 Business EPS guidance. In addition, we have continued to work diligently to progress our major launches and the pipeline. With the filing of Dupixent®, we now have another important product under FDA review which we believe will enhance Sanofi’s growth profile in the coming years.”
Voit lukea tiedotteen kokonaisuudessaan oheisesta PDF-tiedostosta tai linkistä.